Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: Peter Dierks who wrote (242101)	3/15/2008 12:58:54 PM
From: Nikole Wollerstein	Read Replies (2) \| Respond to of 793991

Anybody following Heparin story? What interesting about it that contaminant have not been identified yet. It is highly Unusual. With modern methods of chromatography it is very easy to identify any foreign substance. However in this case 2 weeks already passed and scientist have not been amiable to figure out what it is. Working hypothesis at this point that somebody with good knowledge of organic chemistry and Heparin manufacturing control added some staff that would easily escape detection and identification Heparin Stopped at the Border By MedHeadlines • Mar 15th, 2008 • Category: Drugs, FDA, Poisoning, Prevention, Recalls On Friday, the US Food and Drug Administration (FDA) announced that it is taking action against shipments of heparin coming into the country from China after an influx of reports describing allergic reactions, including four fatalities, which may be linked to contaminated product. All shipments reaching the US border will now be tested for contamination before further distribution. Heparin, a popular blood-thinning prescription medication, has been linked to more than 700 allergic reactions in the US since January 1, 2007. It is believed to be associated with 19 deaths, however FDA spokesperson Janet Woodcock says there have been no new deaths reported since February 28. The current heparin import alert focuses on heparin produced by Baxter International Inc., of Wisconsin. Baxter gets its active ingredient from Scientific Protein Laboratories LLC (SPL), headquartered in Waunakee, Wisconsin. SPL, which maintains plants in China and Wisconsin, claims it is too soon to tell if the contaminated products come from its Chinese facility. FDA officials announced last week that they discovered a significant amount of a suspicious substance, thought to be a contaminant, in samples of some recalled heparin and in the active ingredient used to manufacture it. The substance is said to be “heparin-like” but it has yet to be identified exactly. Baxter issued a recall of most of its heparin products last month after receiving reports of adverse allergic reactions. A heparin manufacturer in Germany issued reports of contaminated heparin last week and ordered a recall of all its products. Rotexmedica GmbH also purchases heparin ingredients from China but not from SPL. Samples of the products Rotexmedica receives from its Chinese supplier, Yantai Dongcheng Biochemicals, is being compared to the heparin recalled by Baxter.